NEEDHAM, Mass. and PALM BEACH GARDENS, Fla., Jan. 4, 2016 /PRNewswire/ -- Tyrogenex, a privately held biopharmaceutical company, today announced it will present a company update during the eighth annual Biotech Showcase™ at the Parc 55 Hilton hotel in San Francisco.
Tyrogenex CEO Michael D. Webb will present a company update on Jan. 11, 2016, at 1:45 pm PST in the Hearst room.
Tyrogenex is developing X-82, an orally-administered dual vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor, for wet age-related macular degeneration (wet AMD) and solid tumors.
For wet AMD, one of the leading causes of blindness for people over the age of 50 that affects more than 1.5 million Americans, the company is enrolling patients in the APEX phase 2 trial for the treatment of wet AMD. This year, Tyrogenex has been invited to present phase 1 data that shows X-82 is well tolerated and has the potential to improve visual acuity at five prestigious ophthalmology conferences: American Academy of Ophthalmologists, the 15th Eurentina Congress, the 12th International Symposium on Ocular Pharmacology and Therapeutics Clinical Conference, Association for Research in Vision and Ophthalmology and Angiogenesis.
In oncology, proof-of-concept studies indicate efficacy and safety of X-82 in solid tumors and that its low toxicity is uniquely suited for combination regimens. It's a potent CSF1R inhibitor, making it a good candidate to combine with certain immunotherapies, such as anti-PD1 or PD-L1 mAb.
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group.
Tyrogenex is a biopharmaceutical company focused on improving the lives of patients with wet AMD and solid tumors by discovering medicines to help provide additional treatment options. Tyrogenex's lead compound is X-82. For more information, visit www.tyrogenex.com
Tyrogenex's lead compound is X-82. X-82 inhibits both VEGF and PDGFR. Tyrogenex believes X-82 targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation. X-82 is currently being evaluated for wet AMD and solid tumors.
About Wet AMD
AMD is the leading cause of blindness for people over the age of 50 in the United States and Europe. There are two forms of the disease, namely "dry" and "wet" AMD. Wet AMD is characterized by the growth of new blood vessels into the central region of the retina. These new and abnormal blood vessels cause severe central vision loss due to retinal damage caused by leakage of the blood vessels and subsequent scar formation.
This press release contains forward-looking statements that are based on company management's current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.
Tyrogenex Corporate Communications